Exelixis, Inc. (EXEL)

US — Healthcare Sector
Peers: AXSM  INCY  SRPT  ACAD  BMRN  VRTX 

Automate Your Wheel Strategy on EXEL

With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EXEL
  • Rev/Share 8.181
  • Book/Share 7.4602
  • PB 4.8551
  • Debt/Equity 0.0884
  • CurrentRatio 3.513
  • ROIC 0.232

 

  • MktCap 9750532660.0
  • FreeCF/Share 2.7473
  • PFCF 13.0206
  • PE 16.3921
  • Debt/Assets 0.0672
  • DivYield 0
  • ROE 0.2774

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade EXEL RBC Capital Mkts Outperform Sector Perform $45 $50 July 8, 2025
Upgrade EXEL Stephens Equal Weight Overweight -- $60 June 24, 2025
Downgrade EXEL Wells Fargo Overweight Equal Weight -- $36 Feb. 24, 2025
Upgrade EXEL Morgan Stanley Equal Weight Overweight $30 $40 Jan. 27, 2025
Downgrade EXEL Oppenheimer Outperform Perform -- -- Jan. 24, 2025
Downgrade EXEL BMO Capital Markets Outperform Market Perform $36 $40 Dec. 20, 2024
Downgrade EXEL BofA Securities Buy Neutral $35 $39 Dec. 17, 2024
Reiterated EXEL RBC Capital Mkts -- Outperform $30 $34 Oct. 16, 2024
Initiation EXEL UBS -- Neutral -- $30 Sept. 19, 2024

News

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
EXEL
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive

EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib although the size of the clinical benefit isn't known yet. Zanzalintinib doesn't seem to have outperformed in head and neck cancer, with the company curtailing development in that indication following phase 2 data from STELLAR-305.

Read More
image for news Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Read More
image for news Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
CLS, EXEL
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).

Read More
image for news 2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
EXEL
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read More
image for news All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
EXEL
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.

Read More
image for news EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
EXEL
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral

EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.

Read More
image for news Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Here's Why Exelixis (EXEL) is a Strong Growth Stock
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
EXEL
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral

Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Read More
image for news What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
ARGX, EXEL
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
EXEL
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
EXEL
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
EXEL
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Read More
image for news Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
EA, EXEL, FOX, UBER, URBN
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.

Read More
image for news Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
EXEL
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
EXEL
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.

Read More
image for news Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
EXEL
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
2 Stocks to Buy With Less Than $50
EXEL, PFE
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.

Read More
image for news 2 Stocks to Buy With Less Than $50
EXEL or ARGX: Which Is the Better Value Stock Right Now?
ARGX, EXEL
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Read More
image for news EXEL or ARGX: Which Is the Better Value Stock Right Now?
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
ALKS, EXEL, IMCR, KNSA, VRNA
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

Read More
image for news 5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
EXEL, KGC, LYFT
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.

Read More
image for news 3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
3 Reasons Growth Investors Will Love Exelixis (EXEL)
EXEL
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Read More
image for news 3 Reasons Growth Investors Will Love Exelixis (EXEL)
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
EXEL
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Read More
image for news Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
EXEL
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Exelixis (EXEL) is a Strong Momentum Stock
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
EXEL
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.

Read More
image for news EXEL Stock Rises on Positive Data From Colorectal Cancer Study
Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
EXEL
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Read More
image for news Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
EXEL
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Positive

Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.

Read More
image for news Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
EXEL
Published: June 22, 2025 by: Business Wire
Sentiment: Neutral

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from.

Read More
image for news Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Here's Why Exelixis (EXEL) is a Strong Value Stock

About Exelixis, Inc. (EXEL)

  • IPO Date 2000-04-17
  • Website https://www.exelixis.com
  • Industry Biotechnology
  • CEO Michael M. Morrissey
  • Employees 1147

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.